by Jason Heaviland | Jun 15, 2026 | Uncategorized
Why Cell Therapy Target Selection Is So Difficult Antibody-drug conjugates (ADCs) and CAR-T therapies have reshaped modern oncology, but their success still depends on one deceptively simple question: are we targeting the right protein? In practice, answering this is...
by Jason Heaviland | Jan 12, 2026
Payload to Patient: Metabolomics in ADC and Immuno-Oncology In this episode of the ChatGJP series, Panome Bio CSO Dr. Gary J. Patti joins Chris Eden to explore real-world applications of metabolomics in antibody–drug conjugates (ADCs) and immuno-oncology. The...
by ODWAdmin | Oct 1, 2025 | Uncategorized
Antibody-drug conjugate (ADC) resistance represents one of the most formidable challenges in precision oncology, with clinical failures often attributed to our limited understanding of the dynamic molecular mechanisms underlying therapeutic escape. Panome Bio’s...
by ODWAdmin | Sep 25, 2025 | Uncategorized
Antibody-drug conjugates (ADCs) represent a paradigm shift in targeted cancer therapy, combining the specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs through sophisticated linker chemistry. Despite remarkable clinical successes...
